Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST TRIAL
2024-515507-18-00Phase 3Authorised
- Sponsor
- University Hospital Odense
- Start
- Sep 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of propofol, midazolam, levetiracetam, fosphenytoin, valproic acid and 3 more in nonconvulsive status epilepticus (NCSE) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Persistence of non-convulsive status epilepticus at 24 hours (treatment failure). Planned start Sep 2024; status: authorised.
02
Drugs
propofolmidazolamlevetiracetamfosphenytoinvalproic acid
03
Conditions
nonconvulsive status epilepticus (NCSE)
Beyond the preview
Go deeper on 2024-515507-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515507-18-00.